Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Alok Khorana, a GI medical oncologist from the Cleveland Clinic, to discuss the latest highlights from the GI ASCO 2025 conference.

We dive into four key studies that are practice-informing and potentially practice-changing:
1. BREAKWATER: We explore the implications of using Encorafenib and Cetuximab in combination with FOLFOX for patients with BRAF V600E mutations, which are associated with poor prognosis.
2. CheckMate-8HW: This study investigates whether dual checkpoint inhibition is more effective than single-agent immunotherapy for MSI-high patients, revealing promising results in progression-free survival.
3. Aspirin in Adjuvant Settings: We discuss the role of low-dose aspirin in reducing recurrence rates for patients with PI3K alterations, highlighting its potential as a practice-changing intervention.
4. STARTER-NET: Finally, we review the findings from the study on Everolimus combined with Lanreotide for neuroendocrine tumors, noting the lack of overall survival benefit.

Tune in for an insightful discussion on these important topics in oncology, and learn how these findings could impact treatment strategies in your practice. Don't forget to like, subscribe, and check out our other episodes for more conference highlights and treatment discussions!

YouTube: https://youtu.be/YOToz3hKYTg

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers

#OncologyBrothers #GIASCO2025 #ColorectalCancer #Immunotherapy #NeuroendocrineTumors #CancerResearch #Podcast

Welcome to the Oncology Brothers Podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Saby George from Roswell Park Comprehensive Cancer Center to discuss the recent approval of subcutaneous nivolumab based on the CheckMate-67T study.
Join us as we delve into:
•⁠  ⁠The study design and findings of CheckMate-67T
•⁠  ⁠The implications of subcutaneous nivolumab for patients and healthcare providers
•⁠  ⁠Safety signals and side effects associated with the new formulation
•⁠  ⁠The significant time savings for patients receiving treatment
•⁠  ⁠Real-world experiences from patients involved in the trial

This episode highlights how the subcutaneous formulation of nivolumab can enhance patient care by reducing time spent in infusion centers while maintaining efficacy and safety.

Tune in to learn more about this exciting advancement in cancer treatment and its potential impact on patient quality of life! Don't forget to like, subscribe, and check out our other episodes for more insights on FDA drug approvals, conference highlights, and treatment algorithms. We are the Oncology Brothers!

YouTube: https://youtu.be/4blP8jqizUQ

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers

Subscribe to our channel for more insights on oncology treatments and patient care!

In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain, the discussion focuses on the evolving role of immunotherapy (IO) in intermediate HCC.

The episode explores multimodal approaches that combine IO and IO-based therapies with loco-regional treatments and highlights the essential role of a multidisciplinary care team.

Drs Nina Sanford (radiation oncologist), Mark Yarchoan (medical oncologist), and Ed Kim (interventional radiologist) join the Oncology Brothers to share their insights on:

• Current treatment options for intermediate HCC, addressing its heterogeneity and standard treatment pathways

• Latest clinical trial data (EMERALD-1, LEAP-012) on combining IO with loco-regional therapies, and the clinical implications

• The importance of effective collaboration within the multidisciplinary team for delivering optimal patient care

• Combining IO with loco-regional therapy and future perspectives in the field

Clinical takeaways

• IO and IO-based treatments are moving earlier in the treatment paradigm for patients with intermediate HCC. Earlier integration of these therapies aims to achieve improved systemic control, allowing loco-regional therapy to target oligoprogression, residual lesions or reduce tumour burden

• Emerging data supports combining systemic and loco-regional therapies for patients with intermediate HCC. EMERALD-1 and LEAP-012 show promising PFS data using IO-based combination regimens like durvalumab + bevacizumab or pembrolizumab + lenvatinib alongside TACE. Long-term OS data are awaited

• Effective communication and coordinated care among specialists, such as medical oncologists, radiation oncologists, hepatologists, and interventional radiologists, are essential to developing optimal treatment strategies for patients with intermediate HCC

Follow us on social media:

•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers

•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers

•⁠ YouTube: https://www.youtube.com/channel/UCjfxKlVho5xWH5ltufj4F4A/

Subscribe to our channel for more insights on oncology treatments and patient care!

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Pashtoon Kasi from City of Hope to discuss the management of side effects associated with key treatments utilized in colorectal cancer, but also in other tumor types. 

We dived deep into two important drug classes: Bevacizumab, an anti-VEGF antibody, and the anti-EGFR antibodies, Panitumumab and Cetuximab. Dr. Kasi provided a comprehensive overview of these targeted therapies, their mechanisms of action, and the common side effects that patients may experience.

Key topics covered in this episode included:
•⁠  ⁠Overview of Bevacizumab and its side effects, including hypertension, proteinuria, and risk of bleeding.
•⁠  ⁠Clinical pearls for managing side effects associated with Bevacizumab.
•⁠  ⁠Discussion on the skin toxicities, nail changes, and electrolyte imbalances related to Panitumumab and Cetuximab.
•⁠  ⁠The importance of preemptive strategies in managing skin rashes and other side effects.
•⁠  ⁠Insights into infusion reactions with Cetuximab and considerations for patient safety.

Join us for this informative discussion that aims to enhance your understanding of these critical therapies and improve patient outcomes. 

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers

Don't forget to check out our other episodes in the Tox Check series, where we explore antibody-drug conjugates and CAR T therapies.
Subscribe to our channel for more insights on oncology treatments and patient care!

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center to discuss the latest highlights from ASH 2024, focusing on key studies in lymphoma.

In this episode, we dive into:
•⁠  ⁠POLARIX Study: An update on the POLARIX trial, exploring the use of Polatuzumab in frontline diffuse large B-cell lymphoma (DLBCL) and its impact on progression-free survival (PFS).
•⁠  ⁠inMIND Study: A look at the promising results of the inMIND study, which evaluates the combination of Tafasitamab with Lenalidomide and Rituximab in the second-line setting for follicular lymphoma.
•⁠  ⁠Triangle Study: Insights into the evolving role of transplant in mantle cell lymphoma and the implications of BTK inhibitors in treatment.
•⁠  ⁠ENRICH Study: Discussion on the potential of Ibrutinib combined with Rituximab in the first-line setting and its comparison to traditional chemoimmunotherapy.

Join us as we unpack these practice-changing studies, discuss their implications for clinical practice, and share insights on managing side effects associated with new therapies.

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers

Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology research and practice!
#OncologyBrothers #ASH2024 #Lymphoma #CancerResearch #Podcast

Join us for another insightful episode of the Oncology Brothers podcast as we dive into the latest breakthroughs in breast cancer research from the San Antonio Breast Cancer Symposium 2024. In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Sara Tolaney from Dana-Farber Cancer Institute to discuss three pivotal studies:

1.⁠ ⁠DESTINY-Breast06 - An update on the efficacy of T-DXd in HER2 low and ultra-low breast cancer patients, highlighting its potential to change treatment paradigms for endocrine refractory disease.
2.⁠ ⁠DESTINY-Breast12 - Exploring the robust intracranial activity of T-DXd in patients with brain metastases and its impact on quality of life.
3.⁠ ⁠PATINA Trial - A groundbreaking study on the use of CDK4-6 inhibitors in combination with trastuzumab and pertuzumab for ER-positive, HER2-positive breast cancer, showcasing impressive progression-free survival rates.

Tune in as we unpack the implications of these studies for clinical practice and discuss the future of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates on oncology research and treatment strategies!

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers

For more information, visit our website: OncologyBrothers.com

#OncologyBrothers #BreastCancer #SABCS2024 #TDXD #PATINA #CancerResearch #Podcast

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. Jame Abraham from the Cleveland Clinic to discuss key abstracts in the hormone receptor-positive breast cancer space from the San Antonio Breast Cancer Symposium 2024.

Episode Highlights:
•⁠  ⁠EUROPA Trial: A phase 3 study comparing endocrine therapy versus radiation therapy in early-stage breast cancer patients over 70. Discover how the results may impact clinical practice and patient decision-making.
•⁠  ⁠TAILORx Study: Updates on the benefits of anthracycline-based chemotherapy for patients with a recurrence score of 31 and above. Learn how this data influences treatment options for younger patients.
•⁠  ⁠PADMA Study: Insights into the role of CDK4/6 inhibitors combined with endocrine therapy versus chemotherapy in aggressive disease settings. Understand why this combination remains the standard of care.
•⁠  ⁠EMBER-3 Study: An exploration of the new oral selective estrogen receptor degrader, imlunestrant, and its promising results in combination with abemaciclib for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

Join us as we delve into these important studies and their implications for the future of breast cancer treatment. Don't forget to check out our other conference highlights from ASH 2024 and SABCS 2024!

Subscribe for more insights and updates in oncology!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]

In the third of this 4-part podcast series on hepatocellular carcinoma (HCC), the Oncology Brothers, Drs. Rahul and Dr Rohit Gosain, are joined by hepatologist Dr. Maria Reig and interventional radiologist Dr. Emil Cohen to explore treatment strategies for patients with intermediate-stage HCC.

The experts share valuable insights into the available treatment options for this heterogeneous patient group and explore the role of systemic treatments and multimodal approaches in achieving optimal patient outcomes.  

The conversation dives deep into real-world clinical challenges in managing patients with intermediate HCC, including treatment sequencing and strategies based on the experts' experience in clinical practice and the available data. The speakers also highlight variations in practice across different centres and geographic regions.

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul & Rohit Gosain are joined by Dr. Laura Huppert from UCSF to discuss key highlights from the San Antonio Breast Cancer Symposium 2024.

We dive into three crucial studies:
1.⁠ ⁠INSEMA Study: Explore the findings on the potential omission of axillary surgery in early-stage hormone receptor-positive breast cancer and its implications for patient quality of life.
2.⁠ ⁠KEYNOTE-522 Update: Learn about the latest insights on the use of Pembrolizumab in triple-negative breast cancer, including the search for predictive biomarkers and the impact of achieving pathological complete response (PCR).
3.⁠ ⁠OlympiA Study Update: Discover the updated results on the use of Olaparib in BRCA-positive patients, highlighting its significant benefits in invasive disease-free survival and overall survival.

Join us as we unpack these important studies and their implications for clinical practice. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Robert Orlowski from MD Anderson Cancer Center to discuss groundbreaking studies presented at ASH 2024 focused on multiple myeloma.

We dived into four key studies:
1.⁠ ⁠AQUILA: Explore the impact of early intervention using daratumumab for smoldering myeloma, which showed improved progression-free survival (PFS) and overall survival (OS).
2.⁠ ⁠Dara Based Quad Therapy: We discuss a meta-analysis reaffirming the use of quadruplet therapy with anti-CD38 for newly diagnosed multiple myeloma as the standard of care.
3.⁠ CARTITUDE-4: study highlights the benefits of CAR-T therapy in earlier lines of treatment for patients with lenalidomide-refractory disease.
4.⁠ ⁠Role of IVIG with BCMA Bispecific Antibodies: Discover how IVIG can reduce infection rates and improve overall survival when used alongside BCMA-targeted therapies.

Tune in for an insightful discussion that will enhance your understanding of the latest advancements in multiple myeloma treatment. Don't forget to check out our other episodes on CLL, myeloma, and lymphoma from ASH 2024!

Subscribe to the Oncology Brothers for more updates and expert insights in oncology!

Website: http://www.oncbrothers.com/ 
X/Twitter: https://twitter.com/oncbrothers 
Contact us at [email protected]

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of Zanidatamab, a bispecific HER2 antibody, for HER2 amplified, unresectable, locally advanced, or metastatic biliary tract cancer.
Join us as we discuss the HERIZON-BTC-01 study with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center and one of the study's authors. We explore the significance of HER2 testing in biliary tract cancers, the study's design, key findings, and the implications for treatment strategies in the community oncology setting.

Key topics include:
• Overview of biliary tract cancer and its treatment landscape
• Study design and patient characteristics from the HERIZON-BTC-01 trial
• Key findings, including overall response rates and duration of response
• The importance of HER2 testing and its implications for treatment sequencing
• Side effect profiles and management strategies for Zanidatamab
• Future directions and ongoing clinical trials

Don't miss this insightful discussion that highlights the exciting advancements in HER2-targeted therapies for biliary tract cancer.
Make sure to subscribe for more updates on recent FDA approvals, treatment algorithms, and conference highlights. We look forward to seeing you at GI ASCO 2025 in person!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]